COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 12/31/2024 | 06/30/2024 | 03/31/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -- | 102.73% | 40.89% | 105.04% | 109.42% |
| Total Depreciation and Amortization | -- | 166.88% | 75.98% | 354.15% | 1,440.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -136.82% | -99.80% | -110.86% | -105.71% |
| Change in Net Operating Assets | -- | 530.25% | 40.14% | 126.42% | -52.43% |
| Cash from Operations | -- | 122.00% | 8.20% | 119.60% | 130.19% |
| Capital Expenditure | -- | -2,895.83% | -1,655.56% | -3,608.33% | -7,190.91% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -700.00% | 54,800.00% | -700.00% | -700.00% |
| Cash from Investing | -- | 50,285.71% | -129.73% | -3,529.73% | -6,650.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -144.00% | -29.88% | -163.41% | -216.42% |
| Issuance of Common Stock | -- | 1,200.00% | -- | 1,200.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -159.56% | -44.90% | -185.03% | -247.46% |
| Foreign Exchange rate Adjustments | -- | -231.11% | 127.31% | 129.01% | 139.93% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | 383.09% | 12.83% | 107.09% | 122.20% |